Melinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare Conference
March 14, 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., March 14, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Cancels Presentation at The Cowen & Company 38th Annual Health Care Conference Due to Inclement Weather
March 13, 2018 16:35 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., March 13, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
March 13, 2018 07:00 ET
|
Melinta Therapeutics
Baxdela™(delafloxacin) Launched February 6, 2018, in U.S. for Adults with ABSSSI Acquired Infectious Disease Business from The Medicines Company on January 5, 2018 First Earnings Report as a Public...
Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe
March 08, 2018 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care Conference
March 02, 2018 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., March 02, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage pharmaceutical company developing and commercializing novel antibiotics to treat...
Melinta Therapeutics To Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018
February 28, 2018 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ (meropenem and vaborbactam) in Patients with cUTI
February 27, 2018 16:05 ET
|
Melinta Therapeutics
- VABOMERE demonstrated a greater numerical overall success rate vs piperacillin-tazobactam - VABOMERE safety profile comparable to piperacillin-tazobactam NEW HAVEN, Conn., Feb. 27, 2018 (GLOBE...
Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina
February 20, 2018 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States
January 29, 2018 07:00 ET
|
Melinta Therapeutics
– Approved for adult patients with acute bacterial skin and skin structure infections (ABSSSI) – – Provides coverage of gram-positive and gram-negative pathogens; only FDA-approved fluoroquinolone...
Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis
January 18, 2018 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...